SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Photo courtesy of Novavax
Genetown
Novavax to Start Phase III COVID-19 Trials in U.S. with Fast Track Designation
Data from this study is expected to support U.S. authorization and approval for their vaccine.
November 9, 2020
 · 
4 min read
 · 
Kate Goodwin
Business
Can Pharma Win Back America?
According to recent polls, less than half of Americans trust pharmaceutical companies. In fact, only 42% of respondents say they have any trust in pharma, with a paltry 6% having a great deal.
November 5, 2020
 · 
4 min read
 · 
Kate Goodwin
Genetown
Do Waning COVID-19 Antibodies Mean Loss of Immunity?
Harvard immunology experts comment on studies regarding antibodies in COVID-19 patients diminishing over time.
November 5, 2020
 · 
5 min read
 · 
Kate Goodwin
Business
Biopharma Acquisitions Plummet in 2020, While Collaborations Grow
The current pandemic has caused a major decrease in big money investments into mergers and acquisitions. Could company collaborations be the skeleton key needed to drive life sciences?
November 5, 2020
 · 
2 min read
 · 
Kate Goodwin
Sundry Photography/Shutterstock
Policy
Abbott Sues Former VP Over Trade Secrets, Similar Cases Expected to Follow in “New Normal”
Abbott is suing their former VP Jerome Clavel over allegations of trade secret theft with intent to share with his new employer, rival diagnostics company Bio-Rad.
November 4, 2020
 · 
3 min read
 · 
Kate Goodwin
Deals
Biopharma Money on the Move: October 28 – November 3
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
November 3, 2020
 · 
4 min read
 · 
Kate Goodwin
Pictured: Scales of justice swing in the air/court
Policy
Prevail and Alector Both Declare Victory in Year-Long Legal Battle
Both sides claim to be pleased with arbitration results in dispute over Prevail CEO’s alleged breach of contract from time with Allector.
November 3, 2020
 · 
3 min read
 · 
Kate Goodwin
Job Trends
Opportunity Horizon – A Look at Recent Life Sciences Job Expansions
The life sciences industry is one of the fastest growing in the world. BioSpace provides a rundown of companies announcing facility and job expansions across the U.S. and beyond.
November 3, 2020
 · 
4 min read
 · 
Kate Goodwin
Deals
PerkinElmer Expands Horizons with $383 Million CRISPR Tech Acquisition
Horizon Discovery Group brings new gene editing and gene modulation tools to PerkinElmer’s expanding life sciences portfolio.
November 2, 2020
 · 
2 min read
 · 
Kate Goodwin
Drug Development
Q32 Stays Busy with $60 Million Series B and First Dose in Phase I Trial
Q32 Bio rakes in $60 million Series B as they dose their first patient in IL-7R antibody trial.
October 29, 2020
 · 
2 min read
 · 
Kate Goodwin
Business
Fauci Predicts First COVID-19 Vaccine by Late December for High-Risk Americans
Fauci said the first COVID-19 vaccines could ship late December or early January.
October 29, 2020
 · 
2 min read
 · 
Kate Goodwin
Drug Development
Enrollment Grows as Clinical Trials Become More Innovative During Pandemic
Recent Greenphire data shows new participant enrollment up 85% since slump in April.
October 28, 2020
 · 
3 min read
 · 
Kate Goodwin
Deals
Biopharma Money on the Move: October 21-27
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
October 27, 2020
 · 
4 min read
 · 
Kate Goodwin
EYSUVIS become the first FDA approved treatment fo
FDA
Kala Gets the Greenlight from FDA for Dry Eye Disease Treatment EYSUVIS
EYSUVIS is the first FDA-approved ocular corticosteroid for the treatment of dry eye disease. Know more about how it got approval and the complete development timeline here.
October 27, 2020
 · 
3 min read
 · 
Kate Goodwin
Policy
Some Manufacturing Sites for COVID-19 Vaccines Can Skip FDA Inspections
While pre-license inspections of manufacturing sites are typically done following the acceptance of a BLA filing, due to the public health emergency of COVID-19, the FDA is instead requiring a quality control unit to be established by each manufacturer with detailed report submissions about their manufacturing processes.
October 26, 2020
 · 
2 min read
 · 
Kate Goodwin
Load More